Oncimmune Holdings Signs New Contract With Roche
May 28 2020 - 2:19AM
Dow Jones News
By Adria Calatayud
Oncimmune Holdings PLC said Thursday that it has signed a new
contract with Swiss pharmaceutical giant Roche Holding AG to
profile autoantibodies in patient samples collected during cancer
immunotherapy trials.
The U.K. immunodiagnostics group said the contract, for the use
of Oncimmune's SeroTag biomarker discovery platform to explore
autoantibody profiles in patients that received cancer
immunotherapy, will start immediately. Initial results are
scheduled to be provided to Roche within three months, with project
completion by November, Oncimmune said.
Oncimmune Chief Executive Adam M Hill said this is the largest
contract the company has signed to date and builds upon the
collaborative work between the two companies in recent months.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
May 28, 2020 03:04 ET (07:04 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2024 to May 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From May 2023 to May 2024